These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 17544870

  • 1. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, Kalsy SA, Burton DD, Baxter KL, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [Abstract] [Full Text] [Related]

  • 2. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people.
    Vazquez Roque MI, Camilleri M, Stephens DA, Jensen MD, Burton DD, Baxter KL, Zinsmeister AR.
    Gastroenterology; 2006 Dec; 131(6):1717-24. PubMed ID: 17087952
    [Abstract] [Full Text] [Related]

  • 3. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 6. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 7. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 8. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
    Hsiao DJ, Wu LS, Huang SY, Lin E.
    Pharmacogenet Genomics; 2009 Sep; 19(9):730-3. PubMed ID: 19687782
    [Abstract] [Full Text] [Related]

  • 9. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 10. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 Sep; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W.
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [Abstract] [Full Text] [Related]

  • 12. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE, Ruiz AM, Monsalve MC, Berber A.
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [Abstract] [Full Text] [Related]

  • 13. Influence of weight reduction by sibutramine on female sexual function.
    Kim KK, Kang HC, Kim SS, Youn BB.
    Int J Obes (Lond); 2006 May; 30(5):758-63. PubMed ID: 16404407
    [Abstract] [Full Text] [Related]

  • 14. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [Abstract] [Full Text] [Related]

  • 15. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions.
    Cremonini F, Camilleri M, Vazquez Roque M, McKinzie S, Burton D, Baxter K, Zinsmeister AR.
    Gastroenterology; 2006 Nov; 131(5):1431-9. PubMed ID: 17101319
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 17. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
    Grudell AB, Sweetser S, Camilleri M, Eckert DJ, Vazquez-Roque MI, Carlson PJ, Burton DD, Braddock AE, Clark MM, Graszer KM, Kalsy SA, Zinsmeister AR.
    Gastroenterology; 2008 Oct; 135(4):1142-54. PubMed ID: 18725220
    [Abstract] [Full Text] [Related]

  • 18. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 19. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.